Logo-jrip
Submitted: 14 Oct 2020
Accepted: 13 Dec 2020
ePublished: 03 Jan 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2021;10(2): e15.
doi: 10.34172/jrip.2021.15

Scopus ID: 85103134411
  Abstract View: 1598
  PDF Download: 999

Original

The serum level of anti-phospholipase A2 receptor antibody does not predict severity of proteinuria in primary membranous glomerulonephritis

Sepideh Hajian 1 ORCID logo, Ali Sarbazi-Golezari 2,3 ORCID logo, Nazanin Samandari 3* ORCID logo

1 Department of Nephrology, Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran
2 Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran
3 Metabolic Diseases Research Center, Research Institute for prevention of Non- Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran
*Corresponding Author: *Corresponding author: Nazanin Samandari, Email: , Email: samandarinazanin72@gmail.com

Abstract

Introduction: Anti-phospholipase A2 receptor (anti-PLA2r) antibody is a marker in blood and has been recently reported that it is increased in patients with primary membranous glomerulonephritis (MGN).

Objectives: To investigate the role of this receptor in severity of proteinuria in pMGN, we evaluated the relationship between serum levels of this receptor and proteinuria in patients with primary MGN.

Patients and Methods: This study was conducted on patients with primary MGN referring to the nephrology clinic in Qazvin province during 2016-2017. Serum level of anti-PLA2r and level of proteinuria before and after medical treatments were measured. anti-PLA2r was measured using the enzyme-linked immunosorbent assay (ELISA) kits.

Results: Anti-PLA2r was positive and negative in 42.3% and 57.7% of the patients with primary MGN, respectively. There was no significant relationship between serum level of anti-PLA2r and level of proteinuria before and after the medical treatments.

Conclusion: Our data show that anti-PLA2r could not predict the severity of proteinuria in patients with primary MGN.

First Name
Last Name
Email Address
Comments
Security code


Abstract View: 1599

Your browser does not support the canvas element.


PDF Download: 999

Your browser does not support the canvas element.